These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26201085)

  • 1. Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin-6 receptor-alpha inhibition with tocilizumab.
    Lee JS; Chapman MJ; Piraino P; Lamerz J; Schindler T; Cutler P; Dernick G
    Proteomics Clin Appl; 2016 Feb; 10(2):183-94. PubMed ID: 26201085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.
    McInnes IB; Thompson L; Giles JT; Bathon JM; Salmon JE; Beaulieu AD; Codding CE; Carlson TH; Delles C; Lee JS; Sattar N
    Ann Rheum Dis; 2015 Apr; 74(4):694-702. PubMed ID: 24368514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
    Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
    Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
    Liao KP; Playford MP; Frits M; Coblyn JS; Iannaccone C; Weinblatt ME; Shadick NS; Mehta NN
    J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis.
    Pozzi FS; Maranhão RC; Guedes LK; Borba EF; Laurindo IM; Bonfa E; Vinagre CG
    J Clin Lipidol; 2015; 9(1):72-80. PubMed ID: 25670363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does a lack of physical activity explain the rheumatoid arthritis lipid profile?
    AbouAssi H; Connelly MA; Bateman LA; Tune KN; Huebner JL; Kraus VB; Winegar DA; Otvos JD; Kraus WE; Huffman KM
    Lipids Health Dis; 2017 Feb; 16(1):39. PubMed ID: 28187765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.
    Hoffman E; Rahat MA; Feld J; Elias M; Rosner I; Kaly L; Lavie I; Gazitt T; Zisman D
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    Naerr GW; Rein P; Saely CH; Drexel H
    Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.
    Robertson J; Porter D; Sattar N; Packard CJ; Caslake M; McInnes I; McCarey D
    Ann Rheum Dis; 2017 Nov; 76(11):1949-1952. PubMed ID: 28916714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism.
    Ronda N; Greco D; Adorni MP; Zimetti F; Favari E; Hjeltnes G; Mikkelsen K; Borghi MO; Favalli EG; Gatti R; Hollan I; Meroni PL; Bernini F
    Arthritis Rheumatol; 2015 May; 67(5):1155-64. PubMed ID: 25605003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
    PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.
    Romano C; Del Mastro A; Sellitto A; Solaro E; Esposito S; Cuomo G
    Clin Rheumatol; 2018 Jun; 37(6):1695-1700. PubMed ID: 29362962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: an anti-interleukin-6 receptor antibody.
    Yanagida M; Kawasaki M; Fujishiro M; Miura M; Ikeda K; Nozawa K; Kaneko H; Morimoto S; Takasaki Y; Ogawa H; Takamori K; Sekigawa I
    Biomed Res Int; 2013; 2013():607137. PubMed ID: 24058910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.